Delphia Therapeutics
Bryan Gutierrez is a seasoned professional in biotechnology and pharmaceutical operations, currently serving as Vice President and Head of Operations at Delphia Therapeutics since August 2023. Prior to this role, Bryan was Principal and VP of Operations at Gordian Ventures from August 2021 to June 2023, where responsibilities included company creation and the management of US operations. Bryan's experience also encompasses leadership positions at Casma Therapeutics, Agios Pharmaceuticals, and Momenta Pharmaceuticals, focusing on program and alliance management, clinical development, and biosimilar programs. Educational qualifications include a Master’s Degree in Biotechnology Management from Harvard University and a Bachelor’s Degree in Exercise and Sports Sciences from the University of Florida.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.